Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
- Written by PR Newswire Asia - Asian Spectator
![]() |
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).
Q1 2026 Highlights
- Q1 2026 unaudited Group revenue of US$230 million, up 11%...




